TY - JOUR
T1 - Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor
AU - Hofmann, Matthias
AU - Pflanzer, Ralph
AU - Zöller, Nadja Nicole
AU - Bernd, August
AU - Kaufmann, Roland
AU - Thaci, Diamant
AU - Bereiter-Hahn, Jürgen
AU - Hirohata, Satoshi
AU - Kippenberger, Stefan
N1 - Funding Information:
Address all correspondence to: Matthias Hofmann, PhD, Department of Dermatology, Venereology and Allergology, Johann Wolfgang Goethe University, Theodor-Stern Kai 7, D-60590 Frankfurt/Main, Germany. E-mail: [email protected] 1This research was supported by the LOEWE PräBionik network of the state of Hesse (BOSS4 to M.H. and R.P.) and by a Japan Society for the Promotion of Science fellowship to M.H. (PE12081). 2These authors contributed equally to this work. Received 11 March 2013; Revised 7 May 2013; Accepted 14 May 2013 Copyright © 2013 Neoplasia Press, Inc. Open access under CC BY-NC-ND license. 1944-7124/13 DOI 10.1593/tlo.13274
PY - 2013/8
Y1 - 2013/8
N2 - Characteristically, most solid tumors exhibit an increased tumor interstitial fluid pressure (TIFP) that directly contributes to the lowered uptake of macromolecular therapeutics into the tumor interstitium. Abnormalities in the tumor-associated lymph vessels are a central brick in the development and prolonged sustaining of an increased TIFP. In the current study, vascular endothelial growth factor C (VEGF-C) was used to enhance tumor-associated lymphangiogenesis as a new mechanism to actively reduce the TIFP by increased lymphatic drainage of the tumor tissue. Human A431 epidermoid vulva carcinoma cells were inoculated in NMRI nu/nu mice to generate a xenograft mouse model. Seven days after tumor cell injection, VEGF-C was peritumorally injected to induce lymphangiogenesis. Tumor growth and TIFP was lowered significantly over time in VEGF-C-treated tumors in comparison to control or VEGF-A-treated animals. These data demonstrate for the first time that actively induced lymphangiogenesis can lower the TIFP in a xenograft tumor model and apparently reduce tumor growth. This model represents a novel approach to modulate biomechanical properties of the tumor interstitium enabling a lowering of TIFP in vivo.
AB - Characteristically, most solid tumors exhibit an increased tumor interstitial fluid pressure (TIFP) that directly contributes to the lowered uptake of macromolecular therapeutics into the tumor interstitium. Abnormalities in the tumor-associated lymph vessels are a central brick in the development and prolonged sustaining of an increased TIFP. In the current study, vascular endothelial growth factor C (VEGF-C) was used to enhance tumor-associated lymphangiogenesis as a new mechanism to actively reduce the TIFP by increased lymphatic drainage of the tumor tissue. Human A431 epidermoid vulva carcinoma cells were inoculated in NMRI nu/nu mice to generate a xenograft mouse model. Seven days after tumor cell injection, VEGF-C was peritumorally injected to induce lymphangiogenesis. Tumor growth and TIFP was lowered significantly over time in VEGF-C-treated tumors in comparison to control or VEGF-A-treated animals. These data demonstrate for the first time that actively induced lymphangiogenesis can lower the TIFP in a xenograft tumor model and apparently reduce tumor growth. This model represents a novel approach to modulate biomechanical properties of the tumor interstitium enabling a lowering of TIFP in vivo.
UR - http://www.scopus.com/inward/record.url?scp=84881048024&partnerID=8YFLogxK
U2 - 10.1593/tlo.13274
DO - 10.1593/tlo.13274
M3 - Journal articles
AN - SCOPUS:84881048024
SN - 1936-5233
VL - 6
SP - 398
EP - 404
JO - Translational Oncology
JF - Translational Oncology
IS - 4
ER -